Introduction {#Sec1}
============

The P2Y receptors are 7TM (containing seven transmembrane domains) receptors that couple to G protein-dependent and -independent signaling pathways, including ion channels \[[@CR1]\]. Eight human subtypes of the P2Y receptor family have been defined. According to a dendrogram relating sequence homology, the P2Y~1~, P2Y~2~, P2Y~4~, P2Y~6~, and P2Y~11~ receptors form a cluster of preferentially G~q~-coupled receptors, and the P2Y~12~, P2Y~13~, and P2Y~14~ receptors form a cluster of preferentially G~i~-coupled receptors \[[@CR2], [@CR3]\].

Elucidation of the medicinal chemistry of agonists and antagonists of the P2Y receptors has lagged behind characterization of many other members of the group A G protein-coupled receptors (GPCRs) \[[@CR4]--[@CR8]\]. Many of the early ligands suffered from promiscuity, affecting not only multiple P2Y metabotropic receptors but also P2X nucleotide-gated ion channels, various enzymes involved in controlling levels of extracellular nucleotides and nucleosides, and intracellular signaling pathways. However, the armamentarium of P2Y receptor ligands available has recently expanded greatly in both quantity and quality. Qualitative and quantitative structure--activity relationships (SARs) were recently constructed in detail for nucleotides acting at P2Y~1~ and P2Y~12~ receptors and with less detail for the P2Y~2~ and P2Y~6~ receptors. Molecular modeling of these receptors and docked ligands with a rhodopsin-based template has aided in ligand design \[[@CR2], [@CR3]\]. Studies of radioligand binding have been successful at only a few of the P2Y receptors. In this review, we identify the most selective molecular probes reported for the P2Y receptors, which have enabled pharmacological studies in the nucleotide field. The availability of pharmacological tools for the various subtypes (along with genetically modified mouse strains) is also enabling biological studies.

The five major native ligands of the P2Y receptors (Fig. [1](#Fig1){ref-type="fig"}) are adenosine 5′-triphosphate (ATP) **1**, adenosine 5′-diphosphate (ADP) **2**, uridine 5′-triphosphate (UTP) **3**, uridine 5′-diphosphate (UDP) **4**, and UDP-glucose **5** (or other UDP sugars). Dinucleotides such as Ap~4~U **6** are also naturally occurring P2Y agonists \[[@CR9]\]. Adenosine monophosphate (AMP) and uridine monophosphate (UMP) are inactive at P2Y receptors. Figure [2](#Fig2){ref-type="fig"} shows the correspondence of these nucleotides and the subtypes that they activate or antagonize, along with the diversity of representative biological effects induced by P2Y receptor activation. Some single nucleotides activate multiple subtypes (e.g., ATP and UTP) or activate one subtype and antagonize another (e.g., ATP and UDP). UDP acts as a competitive antagonist at the human but not rat P2Y~14~ receptor \[[@CR10]\]. Fig. 1**a** Naturally occurring P2Y receptor agonists and terminally thiophosphate-substituted analogues.**b** Structures of adenine-derived nucleotide agonists of P2Y~1~, P2Y~12~, and P2Y~13~ receptorsFig. 2Correspondence of the five principal native ligands of the human P2Y receptors and the subtypes they activate. Note that various dinucleotides also activate P2Y receptors. For example, dinucleoside triphosphates activate the P2Y~6~ receptor

Pharmacological studies of P2Y receptors are complicated by the presence of ectonucleotidases that degrade the native agonist and antagonist nucleotides. Products of the enzymatic hydrolysis might either be inactive or have activity at other P2Y receptor subtypes (e.g., 5′-triphosphate derivatives are converted to diphosphates) or at adenosine receptors (when adenosine is produced by the action of CD73/5′-nucleotidase on AMP \[[@CR11]\]). Alternately, the 5′-diphosphates might be phosphorylated to biologically active 5′-triphosphates by the action of nucleoside diphosphokinase \[[@CR12]\]. Thus, the state of activation of multiple P2Y receptors in a given tissue is a complex function of the kinetics of release, interconversion, and inactivation of the family of receptor-interactive nucleotides.

Various phosphate modifications, such as a terminal thiophosphate substitution, increase stability toward nucleotidases. Thus, ATPγS **7**, ADPβS **8**, UTPγS **9**, and UDPβS **10** have been used to activate P2Y receptors, as noted in Table [1](#Tab1){ref-type="table"}. The terminal thiophosphates are generally well tolerated in the nucleotide-binding sites of the P2Y receptors. However, these compounds are susceptible to oxidation and are difficult to synthesize on a large scale. Thiophosphate substitutions at nonterminal phosphate groups are better tolerated at the P2Y~1~ than at the P2Y~2~ and P2Y~4~ subtypes \[[@CR15], [@CR16]\]. Another type of modification that increases the stability of such nucleotide derivatives is replacement of a bridging oxygen of the phosphate chain with methylene or dihalomethylene; however, this modification tends to reduce potency at the P2Y receptors \[[@CR17]\]. Table 1Potencies and selectivities of natural and synthetic ligands at the human P2Y receptors (references in brackets)Subfamily and Pharmacologic CharacteristicsReceptor SubtypeLigands (potency and selectivity)Native agonistpEC~50~ (ref)Synthetic agonistpEC~50~ (ref)Cross reactivitySynthetic (or native) antagonistpEC~50~ (ref)Cross reactivityP2Y~1~-like, Gq-coupledP2Y~1~ADP 25.09 \[[@CR6]\]MeSADP 128.22 \[[@CR6]\]P2Y~12,13~A3P5P 256.08 \[[@CR35]\]noneADP-β-S^a^ 87.02 \[[@CR6]\]P2Y~12,13~MRS2179 266.48 \[[@CR36]\]noneMRS2365 249.40 \[[@CR34]\]noneMRS2279 297.28 \[[@CR6]\]noneMRS2500 309.02 \[[@CR39]\]noneP2Y~2~UTP **3**8.10 \[[@CR4]\]UTP-γ-S^a^**9**6.62 \[[@CR4]\]noneSuramin **48a**4.32 \[[@CR6]\]P2Y~11~ATP **1**7.07 \[[@CR4]\]NS365 **68c**7.00 \[[@CR4]\]P2Y~4~AR-C126313 **52**6 \[[@CR4],[@CR74]\]INS37217 **69**6.66 \[[@CR4]\]P2Y~4~MRS2576^b^**57**4.04 \[[@CR81]\]P2Y~1,4,6~MRS2698**63b**8.10 \[[@CR64]\]noneP2Y~4~UTP **4**5.60 \[[@CR6]\]2\'-azido-dUTP **64**7.14 \[[@CR12]\]P2Y~4~PPADS **49**\< 5.00 \[[@CR6]\]P2Y~2~ATP **1**4.37 \[[@CR6]\]various (ago), P2Y~12~MRS2577^b^**56**4.01 \[[@CR81]\]P2Y~6~P2Y~6~UDP **4**6.52 \[[@CR6]\]UDP-β-S **10**7.33 \[[@CR4]\]noneMRS2578^b^**55**7.43 \[[@CR4]\]noneINS48823 **71**6.90 \[[@CR4]\]noneMRS2633 **67**6.64 \[[@CR68]\]noneMRS2693 **66**7.83 \[[@CR68]\]NoneP2Y~11~ATP **1**4.77 \[[@CR6]\]AR-C67085 **35**5.05 \[[@CR50]\]P2Y~12,13~ (ant)Suramin **48a**4.79 \[[@CR6]\]P2Y~2~ATP-γ-S^a^**7**5.52 \[[@CR6]\]P2Y~1,2,12~AMP-α-S^a^**18**partial agonist \[[@CR50]\]none P2Y~1~-like, Gi-coupledP2Y~12~ADP **2**7.22 \[[@CR1]\]MeSADP **12**7.85 \[[@CR1]\]P2Y~1,13~MeSAMP **13**4.00 \[[@CR82]\]noneADP-β-S^a^**8**6.72 \[[@CR1]\]P2Y~1,13~ATP **1**3.60 \[[@CR40]\]various (ago), P2Y~4~AR-C67085 **36**4.52 \[[@CR45]\]P2Y~11~ (ago), P2Y~13~AR-C69931MX **37**9.40 \[[@CR40]\]P2Y~11~ (ago), P2Y~13~AZD6140 **38**7.90 \[[@CR45]\]noneINS50589 **40**7.80 \[[@CR41]\]noneClopidogrel^c^**41**5.74 \[[@CR42]\]noneP2Y~13~ADP **2**7.94 \[[@CR84]\]MeSADP **12**7.85 \[[@CR84]\]P2Y~1,12~MRS2211 **50**5.97 \[[@CR83]\]noneAR-C67085 **36**6.67 \[[@CR50]\]P2Y~11~ (ago), P2Y~12~AR-C69931MX **37**8.40 \[[@CR83]\]P2Y~11~ (ago), P2Y~13~P2Y~14~UDP-glucose **75**6.45 \[[@CR71]\]MRS2690 **78**7.31 \[[@CR71]\]noneUDP **4**7.28 \[[@CR10]\]P2Y~6~ (ago)UDP-galactose **76**6.17 \[[@CR71]\]UDP-glucosamine **77**5.36 \[[@CR71]\]a, unstable to oxidation.b, an insurmountable antagonist, which is hydrophobic and reactive toward nucleophiles and aqueous medium.c, active only *in vivo,* through a thiol-reactive metabolite.ago, agonist; ant, antagonist

The P2Y receptor agonists are nearly exclusively nucleotide derivatives, which presents barriers to drug development because of their instability, low bioavailability, nonspecific binding to biological membranes, and tedious synthesis, purification, and structural verification. Screening of small-molecule ligands of diverse structure has not yet been carried out extensively for the P2Y family. Radioligand binding is effective for ligand screening in many other GPCRs, but biological assays at the P2Y receptors usually exploit functional endpoints, e.g., typically G~q~-stimulated phospholipase C-β for the P2Y~1~-like subfamily (Table [1](#Tab1){ref-type="table"}). Suitable radioligand-binding methods are only available for the P2Y~1~ and P2Y~12~ receptors \[[@CR18], [@CR19]\]; those methods were developed after many attempts to use radiolabeled nucleotides were reported in the literature and later proved unsatisfactory.

Adenine nucleotide-responsive P2Y receptors {#Sec2}
===========================================

SAR of P2Y~1~, P2Y~12~, and P2Y~13~ receptors for 5′-diphosphates {#Sec3}
-----------------------------------------------------------------

The most prominent regions of distribution of these ADP-responsive receptors are P2Y~1~ (platelets, endothelial cells, brain), P2Y~12~ (platelets, brain), and P2Y~13~ (immune system, dendritic cells). There is no striking sequence homology between the P2Y~1~ receptor and P2Y~12~ or P2Y~13~ receptors. The sequence identity of the TM domains of the human P2Y~1~ is 26.9% and 28.0% for the P2Y~12~ and P2Y~13~ receptors, respectively. In contrast, the sequence identity within the TM domains of the P2Y~12~ and P2Y~13~ receptors is 57.0%.

**Modification of the phosphate moiety** ADP **2** is the principal endogenous agonist at the P2Y~1~, P2Y~12~, and P2Y~13~ receptors. ATP **1** interacts with less affinity and efficacy than ADP at the P2Y~1~ and P2Y~12~ receptors. At P2Y~12~ receptors, the loss of efficacy is pronounced, such that ATP and other 5**′**-triphosphate derivatives act as antagonists. At P2Y~13~ receptors, ADP and ATP both act as full agonists.Modifications of the di- and triphosphate moieties of the nucleotide ligands have been probed for effects on P2Y receptor activity (Fig. [1](#Fig1){ref-type="fig"}). For example, when an ionizable oxygen of the α-phosphate of the triphosphate moiety of adenine nucleotide derivatives is substituted with a BH~2~ moiety, it favors P2Y~1~ receptor potency \[[@CR20]\]. Thus, the P2Y~1~ receptor can be activated by a 5′-(1-boranotriphosphate) derivative **14** of 2-methylthio-ATP **11**. Separation of two stable isomers of **14** demonstrated stereoselectivity in activation of the rat P2Y~1~ receptor (EC~50~ = 2.6 nM, for the more potent R-isomer of **14**).

**Modification of the adenine moiety** The SAR around the adenine moiety of the nucleotides has been extensively explored at the P2Y~1~ and P2Y~12~ receptors. Broad freedom of substitution has been observed at the C2 position, and sterically bulky groups and extended chains at this position are often tolerated in receptor binding.A small hydrophobic pocket in the receptor-binding site surrounds the *N*^6^-position of adenine nucleotides acting as P2Y~1~ agonists and antagonists \[[@CR21]\], and the P2Y~12~ receptor has a considerably larger pocket \[[@CR22]\]. Amino, ether, and thioether derivatives at the 2-position of the adenine ring of ATP were compared in P2Y~1~ potency; thioethers, in general, are the most potent \[[@CR23]\].2-Alkylthio and 2-(arylalkylthio) ethers of ADP are highly potent agonists at these subtypes (Fig. [1](#Fig1){ref-type="fig"}b) \[[@CR24], [@CR25]\]. 2-Methylthio-ADP **12** is a potent agonist (EC~50~ in nM) at human P2Y~1~ (3), rat P2Y~12~ (1), and human P2Y~13~ (1) receptors \[[@CR2], [@CR7], [@CR26]\]. 2-Methylthio (2-MeS)-ATP **11** is less potent (EC~50~ = 8 nM) than **12** at the P2Y~1~ receptor and also less selective because certain P2X receptors are activated \[[@CR26]\]. A 2-\[2-(4-aminophenylethyl)\] 5′-triphosphate derivative **15** exhibits an EC~50~ of 1 nM at the P2Y~1~ receptor, and a related azido 5′-diphosphate derivative **16** serves as a photoaffinity label of P2Y receptors in platelets \[[@CR27]\]. 2-Alkynyl substituents on adenine nucleotide analogues provide high potency as either P2Y~1/12~ receptor agonists or antagonists \[[@CR28]\].Although AMP is inactive at the P2Y~1~ receptor, adding a 2-thioether substituent as a receptor "anchor" allows adenosine 5′-monophosphate analogues to bind to and activate the P2Y~1~ receptor. Among these derivatives, 2-(hexylthio) (HT)-AMP **17** is especially potent, with an EC~50~ of 59 nM at the turkey P2Y~1~ receptor \[[@CR29]\]. 2-MeS-AMP **13** weakly activates the P2Y~1~ receptor but also acts as a weak antagonist of the P2Y~12~ receptor \[[@CR30]\]. α-Thio ATP derivatives, such as compound **18**, are potent P2Y~1~ receptor agonists (EC~50~ = 17 nM). The corresponding α-thio AMP derivatives are weak as P2Y receptor agonists, but the simultaneous inhibition of ATP diphosphohydrolase \[ecto-apyrase nucleoside triphosphate diphosphohydrolase-1 (NTPDase1) or CD39, present in blood, neuronal, endothelial, pancreatic, and smooth muscle cells \[[@CR31]\]\] complicates their use as pharmacological probes \[[@CR15]\].Limited alteration of the heterocyclic ring of P2Y-active nucleotides is possible. 8-Aza and 1-deaza modifications are generally tolerated at P2Y~1~ and P2Y~12~ receptors \[[@CR22], [@CR34], [@CR87]\], but other modifications, such as N1, N6-etheno, result in inactivity at P2Y receptors \[[@CR32]\]. A fluorescent derivative of ATP **19** containing a tricyclic nucleobase is strikingly potent in activation of the P2Y~1~ receptor \[[@CR33]\].

**Modification of the ribose moiety** Replacement of the ribose 2′ and/or 3′ hydroxyl groups with H in adenine nucleotide agonists greatly reduces the potency at P2Y~1~ receptors. A 1,5-anhydrohexitol bisphosphate derivative **20** activates the P2Y~1~ receptor (EC~50~ = 6.29 μM at turkey P2Y~1~ receptor) \[[@CR34]\] (Fig. [1](#Fig1){ref-type="fig"}b).

Simple carbocyclic (cyclopentyl) analogues of ATP enhance antagonist affinity at the P2Y~12~ receptor \[[@CR22]\]. Among the more successful examples of the use of carbocyclic or sterically constrained carbocyclic substitution of the ribose moiety for P2Y receptor interactions are the bicyclic "methanocarba" analogues \[[@CR35], [@CR36]\]. Two isomeric forms of the methanocarba (bicyclo\[[@CR3].1.0\]hexane) ring system have been used as ribose replacements in ATP, representing a North (N), 2′-*exo* envelope **21** or South (S), 2′-*endo* envelope **22** conformation. The addition of a 2-MeS group to **21** to form **24** provides a highly potent and selective P2Y~1~ agonist, MRS2365 (EC~50~ = 0.40 nM) \[[@CR37]\]. Unlike 2MeS-ADP, this compound does not activate P2Y~12~ or P2Y~13~ receptors \[[@CR38]\]. (N)-methanocarba derivative **23** is a full agonist at the P2Y~1~ receptor (EC~50~ = 158 nM); the corresponding 9-riboside, β,γ-methylene-ATP, is a partial weak agonist at that subtype.

A successful approach to designing potent and selective P2Y~1~ receptor antagonists became possible with the observation by Boyer et al. that naturally occurring adenosine bisphosphate derivatives such as A3P5P **25** (Fig. [3](#Fig3){ref-type="fig"}a) act as partial agonists or antagonists of the receptor (EC~50~ = 0.83 μM) \[[@CR39]\]. This has led to improved 2′-deoxyribose 3′,5′-bisphosphate derivatives MRS2179 **26** (EC~50~ = 0.33 μM) and MRS2216 **27** (EC~50~ = 0.21 μM), which are potent and selective P2Y~1~ receptor antagonists \[[@CR34]\]. A C-nucleotide-based antagonist **28** of the P2Y~1~ receptor is patterned after MRS2179 \[[@CR40]\]. (N)-methanocarba substitution within the family of bisphosphate antagonists yields MRS2279 **29** and MRS2500 **30**, which display nanomolar potency at the P2Y~1~ receptor (EC~50~ = 52 nM and 0.95 nM, respectively) \[[@CR18]\]. Moderate antagonist activity at the P2Y~1~ receptor is retained after removal of the 5′-phosphate group of MRS2500 in **31** (EC~50~ = 1560 nM) \[[@CR41]\]. Fig. 3Structures of nucleotide-based antagonists of P2Y~1~ and P2Y~12~ receptors

Acyclic bisphosphate antagonists of the P2Y~1~ receptor and related derivatives **32**--**35** have been characterized \[[@CR42], [@CR43]\]. Short alkyl chains bearing two phosphate groups attached at the adenine 9-position are favored over long chains. The bisphosphate derivative MRS2298 **32** is a potent antagonist of the P2Y~1~ receptor (binding K~i~ = 29.6 nM, human). MRS2496 **34** is a bisphosphonate derivative, which remains tolerated in the P2Y~1~ receptor binding site (binding K~i~ = 76 nM, human). Compound **35**, which contains a cycloproyl ring within the 9-alkyl subsituent, is a P2Y~1~ antagonist with micromolar affinity. Although various phosphate derivatives of the adenine 9-ribosides (cyclic) may be either agonists or antagonists of the P2Y~1~ receptor, only antagonism has been achieved in the acyclic series.

The observation that ATP analogues inhibit platelet aggregation by antagonism of the P2Y~12~ receptor enabled development of the 5′-triphosphate derivatives AR-C67085 (EC~50~ = 30 μM) **36** and AR-C69931MX **37** (Cangrelor, EC~50~ = 0.4 nM) as antithrombotic agents, which were in clinical testing \[[@CR44]\] (Fig. [3](#Fig3){ref-type="fig"}b). Other nucleoside--nucleotide derivatives were investigated for P2Y~12~ receptor antagonism \[[@CR42], [@CR45]\]. For example, AZD6140 **38a** is an uncharged nucleoside-based antagonist of the P2Y~12~ receptor of high potency (pIC~50~ = 7.9) that has been in clinical trials \[[@CR22], [@CR89]\]. A similar carbocyclic derivative **38b** containing a 1H-tetrazol-5-yl group was recently reported to bind to the P2Y~12~ receptor with an IC~50~ value of 2 nM \[[@CR87]\]. The (1*R*,2*S*)-2-phenylcyclopropyl derivative **38b** was found to be 30-fold more potent than the corresponding (1*S*,2*R*) isomer. The uncharged nucleoside derivative MRS2395 **33** \[2,2-dimethyl-propionic acid 3-(2-chloro-6-methylaminopurin-9-yl)-2-(2,2-dimethyl-propionyloxymethyl)-propyl ester\] is a weak antagonist of the P2Y~12~ receptor \[[@CR5]\]. The ADP derivative INS49266 **39** (EC~50~ = 0.052 μM) and the AMP derivative INS50589 **40** (EC~50~ = 0.011 μM) act as potent competitive antagonists of the P2Y~12~ receptor \[[@CR46]\].

Nonnucleotide antagonists of P2 receptors have also been identified and modified to achieve P2Y~12~ receptor selectivity (Fig. [4](#Fig4){ref-type="fig"}). The clinical success of the thienopyridine clopidogel **41** as an antithrombotic agent has stimulated the development of other P2Y~12~ antagonists. The thienopyridines act as liver-activated prodrugs that are irreversible inhibitors of the P2Y~12~ receptor \[[@CR47]\]. Thiol **41b** is reported to be the active metabolite of clopidogrel. Prasugrel **42** is a P2Y~12~ antagonist with similar action, which shows clinical promise \[[@CR48]\]. Fig. 4Structures of nonnucleotide antagonists of P2Y receptors

Competitive antagonists of P2Y~12~ receptors that do not require chemical conversion to an active species in vivo and that are nonnucleotides, i.e., not highly charged phosphate derivatives, are also sought as antithrombotic agents \[[@CR45]\]. Screening of compound libraries has aided hit-and-lead identification in this effort. Compound **43** is a tricyclic benzothiazolo\[2,3-c\]thiadiazine antagonist of the P2Y~12~ receptor (EC~50~ = 0.18 μM) \[[@CR19]\]. Compound **44** is a competitive P2Y~12~ receptor antagonist \[[@CR49]\]. The directly acting (i.e., not requiring chemical transformation in vivo prior to interacting with the receptor) P2Y~12~ antagonist BX677 **45** exhibits a wider therapeutic index than does clopidogrel in experimental models of thrombosis \[[@CR50]\]. Other nonnucleotide heterocyclic derivatives have been discovered that act as selective P2Y~1~ receptor antagonists \[[@CR51]\]. Recently, PRT128 (structure not disclosed) was introduced as an orally active direct-acting and reversible P2Y~12~ receptor antagonist \[[@CR88]\].

Other classes of nonnucleotide antagonists of P2 receptors have also been identified and modified to achieve P2Y receptor selectivity (Fig. [4](#Fig4){ref-type="fig"}). Derivatives of pyridoxal phosphate, e.g., pyridoxal-phosphate-6-azophenyl-2′,4′-disulfonate (PPADS) **49**, are generally relatively nonselective antagonists of the P2Y~1~ receptor and other subtypes \[[@CR4]\]. The SAR of P2 receptor antagonists derived from pyridoxal phosphate was reviewed by Lambrecht and coworkers \[[@CR52]\]. Pyridyl isatogen **51** antagonizes the P2Y~1~ receptor.

Recently, a nonnucleotide antagonist of the P2Y~1~ receptor **47** has been reported through chemical optimization of a library hit \[[@CR86]\]. This compound has a Ki value of 90 nM at the human P2Y~1~ receptor and is proposed for use as an antithrombotic agent. It is orally bioavailable with a half life in rats of 2.8 h.

A moderately selective antagonist of the P2Y~13~ receptor, MRS2211 **50**, has been identified \[[@CR53]\]. Nucleotide derivatives AR-C67085 **36** (EC~50~ = 4 nM) and AR-C69931MX **37** (EC~50~ = 213 nM) potently antagonize the P2Y~13~ receptor.

SAR of P2Y~11~ and P2Y~2~ receptors for 5′-triphosphates {#Sec4}
--------------------------------------------------------

### P2Y~11~ receptor agonists {#Sec5}

Ten years ago, the human P2Y~11~ receptor was cloned from human placenta \[[@CR54]\]. This P2Y receptor subtype is also found on lymphocytes, kidney, and pancreatic-duct epithelial cells \[[@CR55], [@CR56]\]. The P2Y~11~ receptor exhibits moderate amino acid identity with other P2Y receptors. The P2Y~1~ receptor is the closest homologue of the P2Y~11~ receptor subtype, with 37.8% identity in the TM domains. The amino acid identity of the TM domains of the P2Y~11~ receptor with the P2Y~2~ receptor is 35.2%. The P2Y~11~ receptor demonstrates the least homology (20%--22%) with the P2Y~12~-like receptor subfamily.

As with the P2Y~1~ and P2Y~2~ receptors, the P2Y~11~ receptor can be activated by adenosine 5′-triphosphate (ATP) **1**, which is its native agonist. ATP-induced activation of the P2Y~11~ receptor stably expressed in CHO-K1 cells and in 1321N1 astrocytoma cells results in accumulation of both cyclic AMP and IP~3~. These findings indicate that the P2Y~11~ receptor is coupled to both the adenylyl cyclase (via G~s~) and the phosphoinositide (via G~q~) pathways \[[@CR54], [@CR57]\].

It was suggested that nonadenine triphosphates, including UTP **3**, guanosine 5′-triphosphate (GTP), cytidine 5′-triphosphate (CTP), thymidine 5′-triphosphate (TTP), inosine 5′-triphosphate (ITP), and UDP **4** are inactive at the P2Y~11~ receptor \[[@CR54], [@CR57]\]. Another report characterized UTP as a Ca^2+^-mobilizing agonist in P2Y~11~ receptor-expressing 1321N1 astrocytoma cells, whose potency and maximal response are similar to ATP. However, the production of IP~3~ does not increase during activation of the P2Y~11~ receptor by UTP \[[@CR58]\].

Dinucleotide polyphosphates activate various subtypes of P2Y receptors \[[@CR59]\] (Fig. [5](#Fig5){ref-type="fig"}b). At the P2Y~1~ receptor, diadenosine pentaphosphate (Ap~5~A **70c**, EC~50~ = 0.32 μM) is more potent than ATP (EC~50~ = 0.65 μM), and Ap~3~A **70a** (EC~50~ = 0.011 μM) is equipotent to ADP (EC~50~ = 0.014 μM) \[[@CR60]\]. However, none of the diadenosine polyphosphates activate the P2Y~11~ receptor, with the exception of Ap~4~A **70b**, which increases the level of intracellular \[Ca^2+^\] at a concentration of 1 mM \[[@CR54], [@CR57], [@CR61]\]. Fig. 5Structures of additional uracil-derived nucleotide agonists of P2Y~2~, P2Y~4~, P2Y~6~, and P2Y~14~ receptors

Experiments performed on human P2Y~11~ receptor-infected 1321N1 astrocytoma cells indicated increased intracellular production of IP~3~ and cyclic AMP followed by elevation of Ca^2+ ^induced by nicotinamide adenine dinucleotide **72** (*β*-NAD^+^) in a concentration range of 1--100 μM \[[@CR62]\]. Thus, extracellular *β*-NAD^+ ^appears to be an agonist of the P2Y~11~ receptor \[[@CR12]\]. Moreover, nicotinic acid adenine dinucleotide phosphate **73** (NAADP^+^) also activates the P2Y~11~ receptor \[[@CR63]\].

Various analogues of ATP **1** have been examined as potential agonists of the P2Y~11~ receptor (Fig. [1](#Fig1){ref-type="fig"}). The rank order of agonist potency is ATP \> ADP \>\> AMP = adenosine in erythroleukemic K562 cells and in acute monocytic leukemia U937 cells stably transfected with the P2Y~11~ receptor (K11 and U11 cells, respectively) \[[@CR64]\]. NB4 promyelocytic cells behave similarly \[[@CR16]\]. ATP-γ-S **7** is a more potent P2Y~11~ receptor agonist than ATP in 1321N1, CHO-K1, U11, K11, and NB4 cells. Also in U11 and K11 cells, ATP-α-S and ADP-β-S **8** are more potent than ATP. Interestingly, ADP-β-S produces no agonist effect at the P2Y~11~ receptor in NB4 cells \[[@CR65]\]. Adenosine 5′-thiomonophosphate (α-thio-AMP) is almost inactive at the P2Y~11~ receptor \[[@CR64], [@CR65]\].

BzATP (2′ or 3′-O-(4-benzoyl)benzoyl-ATP) is equipotent to ATP-γ-S in 1321N1, CHO-K1, U11, and NB4 cell lines. In contrast, in K11 cells, BzATP (EC~50~ = 63 μM) is one of the weakest P2Y~11~ receptor agonists. Interestingly, 2′-dATP is a more potent agonist of this receptor than ATP in all these cell lines \[[@CR54], [@CR57], [@CR64]\].

Replacement of the α,β- or β,γ-oxygen atom by a methylene group decreases the potency of the ligand in comparison with ATP \[[@CR64], [@CR65]\]. Also, 2-MeS-ATP **11** is weaker than ATP at the P2Y~11~ receptor subtype expressed in 1321N1, CHO-K1, and U11 cells but not in K11 cells. In addition, 2-Cl-ATP is a weak P2Y~11~ receptor agonist \[[@CR66]\]. However, 2-propylthio-β,γ-dichloromethylene-ATP (AR-C67085, **36**, an antagonist of the P2Y~12~ receptor) is the most potent reported agonist of the P2Y~11~ receptor (EC~50~ = 8.9 μM) \[[@CR57], [@CR67]\].

The effects of replacement of the ATP ribose moiety by a (N)- or a (S)-methanocarba-constrained carbocyclic ring were studied at the human P2Y~4~ receptor \[[@CR36]\]. The potency of (N)-methanocarba-ATP **21** (EC~50~ = 34.5 μM) is equivalent to unmodified ATP (EC~50~ = 17 μM). In contrast, (S)-methanocarba-ATP **22** produces no effect at the P2Y~11~ receptor at a concentration of 100 μM. It is possible that not only (N)-methanocarba analogues but also the (N)-conformation of the ribose ring of ATP analogues are preferred at the P2Y~11~ receptor. In addition, these data demonstrate that the oxygen atom of the ATP ribose ring is not essential for agonist potency.

The preferences of green fluorescent protein (GFP)-tagged P2Y~11~ receptor stably expressed in 1321N1 astrocytoma cells for ATP-α-S and ATP-α-S diastereoisomers were the focus of recent studies \[[@CR66]\]. Rp-ATP-α-S (EC~50~ = 0.27 μM) and Sp-ATP-α-B (EC~50~ = 0.34 μM) isomers are more potent than their respective Sp (EC~50~ = 1.71 μM) and Rp (EC~50~ = 2.38 μM) isomers. Moreover, these compounds are more potent than ATP (EC~50~ = 2.83 μM). In addition, both Rp- and Sp-2-MeS-ATP-α-S (EC~50~ = 0.64 and 2.64 μM) are more potent at the P2Y~11~ receptor than is 2-MeS-ATP (EC~50~ = 13.8 μM) \[[@CR66]\]. Interestingly, for the P2Y~1~ receptor, these ligands display the opposite stereoselectivity, but for the P2Y~2~ and P2Y~4~ receptors, Rp-UTP-α-S (EC~50~ P2Y~2~ = 5.4 μM, EC~50~ P2Y~4~ = 27 μM) is more potent than the Sp-UTP-α-S- analogue (EC~50~ P2Y~2~ = 14 μM, EC~50~ P2Y~4~ = 81 μM) \[[@CR16]\].

Various nonnucleotide derivatives have been shown to inhibit P2Y~11~ receptors (Fig. [4](#Fig4){ref-type="fig"}). Suramin **48a**, a drug used to treat trypanosomiasis and onchocerciasis, weakly antagonizes various P2Y and P2X receptors, and its SAR is known in detail \[[@CR52]\]. Suramin also inhibits G protein signaling intracellularly. P2Y~11~ receptor antagonists derived from suramin exhibit nanomolar potency \[[@CR68]\]. NF157 **48b** has a pK~i~ value of 7.35 at the P2Y~11~ receptor and displays the following selectivity ratios (x-fold) over P2Y~1~ (\>650), P2Y~2~ (\>650), P2X~2~ (1), P2X~2~ (3), P2X~3~ (8), P2X~4~ (\>22), and P2X~7~ (\>67) receptors.

### ATP derivatives as P2Y~2~ receptor agonists {#Sec6}

The P2Y~2~ receptor is activated by both uracil and adenine 5′-triphosphates (Fig. [1](#Fig1){ref-type="fig"}). The SAR of UTP derivatives at the P2Y~2~ receptor are treated separately below.

In contrast to UTP **3**, which can activate only P2Y~2~ and P2Y~4~ receptors, ATP **1** is an agonist for three P2Y receptor subtypes P2Y~2~ (EC~50~ = 0.085 μM), P2Y~1~ (EC~50~ = 1.5 μM), and P2Y~11~ (EC~50~ = 17.3 μM) \[[@CR36]\]. For this reason the design of ATP analogues with P2Y~2~ receptor selectivity is a difficult problem.

BzATP and ATP-γ-S are weaker than ATP, and ATP-α-S is inactive at the mouse P2Y~2~ receptor \[[@CR69], [@CR70]\]. Substitution of the α,β-oxygen atom of ATP by a methylene group (α,β-MeATP) results in a ligand that is virtually ineffective at the P2Y~2~ receptor \[[@CR71]\]. In addition, replacement of the β,γ oxygen atom in the 5′-triphosphate chain of ATP by a β,γ-methylene or β,γ-imido group leads to ligands with no effect at the P2Y~2~ receptor at concentration of 1 mM \[[@CR69], [@CR70]\]. Although the P2Y~1~ receptor can be potently activated by 2-MeS-ATP **11**, this ligand is inactive at the P2Y~2~ subtype. However, 2-Cl-ATP is a weak agonist of the P2Y~2~ receptor (EC~50~ = 2.30 μM). The potency of 8-Br-ATP is reported to be EC~50~ = 23.0 μM \[[@CR72]\].

Studies of the preferred conformation of the ribose ring indicate that at the P2Y~2~ receptor (N)-methanocarba-ATP (**21**, EC~50~ = 0.091 μM) and (N)-methanocarba-UTP (**62**, EC~50~ = 0.0159 μM) are equipotent to ATP and UTP, respectively. In contrast, (S)-methanocarba-ATP (**22**, EC~50~ = 3.7 μM) is significantly weaker than ATP.

Uracil nucleotide-responsive P2Y receptors {#Sec7}
==========================================

SAR of P2Y~2~ and P2Y~4~ receptors for 5′-triphosphates {#Sec8}
-------------------------------------------------------

The most prominent tissues of distribution of these UTP-responsive receptors are P2Y~2~ (vascular cells, epithelial cells) and P2Y~4~ (gastrointestinal cells, placenta, cochlear cells). These two receptors display the highest identity in the sequences of their TM domains (66.8%) of all P2Y receptor subtypes.

**Phosphate modifications and dinucleotides** The P2Y~2~ receptor is activated nearly equipotently by UTP **3** (EC~50~ = 0.049 μM) and ATP **3** (EC~50~ = 0.085 μM) (Fig. [1](#Fig1){ref-type="fig"}). However, it is not activated by the 5′-diphosphates UDP **4** and ADP **2**. An early publication showed UDP to be active, but this was later attributed to the presence of UTP in commercial preparations of UDP \[[@CR73]\]. Uridine γ-thiodiphosphate (UTP-γ-S) **9** is a selective agonist for P2Y~2~ (EC~50~ = 0.24 μM) and P2Y~4~ (EC~50~ = 1.6 μM) receptors \[[@CR43]\].

The P2Y~2~ receptor is activated by dinucleotide molecules \[[@CR72]\] as well as uracil or adenine triphosphates. The dinucleotides Up~4~U (INS365, Diquafosol) **68c** and Up~4~dC (INS37217, Denufosol) **69** (Fig. [5](#Fig5){ref-type="fig"}) have the optimal phosphate chain length for activation of the P2Y~2~ receptor (EC~50~ = 0.1 and 0.22 μM) and tend to be more resistant to degradation by nucleotidases than nucleoside triphosphates \[[@CR59], [@CR60]\]. Up~4~-\[5′\]-ribose **74** activates the P2Y~2~ receptor with an EC~50~ of 1.88 μM, i.e., ninefold less potent than Up~4~U **68c**. Up~4~-\[5′\]-ribose **74** still activates the P2Y~2~ receptor and serves as a truncated form of Up~4~U **68c** for purposes of modeling receptor docking \[[@CR74]\]. On the other hand, Up~2~U **68a**, containing only two phosphate groups, is nearly inactive as an agonist, and Up~6~U **68d** is 98-fold weaker than Up~4~U at the P2Y~2~ receptor.

The model of receptor-docked Up~4~U is consistent with a tetraphosphate chain having the optimal length for dinucleotide binding \[[@CR74]\]. The phosphate side chain of diuridine diphosphates apparently is too short to allow uridineII to reach its binding pocket. However, in the case of Up~6~U, its phosphate chains are too large to be fully accommodated inside the receptor. Also, as discussed by Brunschweiger and Müller \[[@CR4]\], among various linear dinucleotides, only dinucleoside tetraphosphates have the same number of negatively charged oxygen atoms as UTP.

**Ribose and uracil modifications** Both 2′-deoxy-2′-amino-UTP and 2-thio-UTP **63a** preserve the agonist potency of UTP at the P2Y~2~ receptor (Fig. [5](#Fig5){ref-type="fig"}a). Combination of these two modifications yields 2′-amino-2-thio-UTP, compound **63b**, synergizes to enhance both potency (8 nM EC~50~) and selectivity (300-fold P2Y~2~-selective versus P2Y~4~). 2′-Amine acetylation reduces potency, and trifluoroacetylation produces intermediate potency.

Modification at position 5, such as 5-bromo-UTP (EC~50~ = 0.75 μM) and 5-iodo-UTP (EC~50~ = 0.83 μM), suggests that introducing a small hydrophobic group might be beneficial at the P2Y~2~ receptor. However, 5-methyl UTP (EC~50~ = 0.48 μM) does not enhance potency, and the 5-amino (EC~50~ = 5.6 μM) and 5-azido (EC~50~ = 1.8 μM) analogues are less potent at the P2Y~2~.

2′-Deoxy-UTP (EC~50~ = 1.08 μM) is 22-fold less potent than UTP (EC~50~ = 0.049 μM); replacement of the 2′-hydroxyl group by a 2′-methoxy group (EC~50~ = 14.3 μM) reduces the potency further (290-fold weaker than UTP). Thus, the hydroxyl group at the 2′-position appears to be important for agonist activities as a donor of H-bonding to the P2Y~2~ receptor.

AR-C126313 **52** and its higher-molecular-weight analogue AR-C118925 **53** are selective antagonists of the P2Y~2~ receptor \[[@CR75]\] (Fig. [4](#Fig4){ref-type="fig"}). Recently, flavonoid derivatives, e.g., **54**, \[[@CR76]\], and derivatives of Reactive Blue 2 **46a**, such as 1-amino-4-(2-methoxyphenyl)-2-sulfoanthraquinone (PSB-716) **46b** \[[@CR77]\], have been explored as P2Y~2~ receptor antagonists. Flavonoid antagonists reduce the amplitude of the P2Y~2~ receptor response to UTP but not the EC~50~ value, indicating allosteric antagonism \[[@CR76]\].

New ligand tools are needed to distinguish P2Y~2~ and P2Y~4~ receptor subtypes pharmacologically and to extend the characterization of the few existing tools to a wider range of species. Selective antagonists of the P2Y~4~ receptor have not yet been identified. Suramin **48a** is more potent as a competitive antagonist at the human P2Y~2~ receptor than at the P2Y~4~ receptor \[[@CR4], [@CR5]\]. The order of potency of agonists is useful in this regard \[[@CR16]\]. 2′-Azido-2′-deoxyUTP **64** is fivefold more potent in activation of phospholipase C (PLC0 at the human P2Y~4~ receptor than at the P2Y~2~ receptor (EC~50~ = 0.54 μM *vs.* 0.78 μM). 4-Thio-UTP (EC~50~ = 0.023 μM) is 15-fold more potent than 2-thio-UTP (EC~50~ = 0.35 μM) in activating the human P2Y~4~ receptor.

SAR of P2Y~6~ receptor for 5′-diphosphates {#Sec9}
------------------------------------------

The major tissue distribution of these UDP-responsive receptors includes vascular smooth muscle cells, microglial cells, and neutrophils. This receptor exhibits significant homology with the TM domains of other P2Y~1~-like receptors, such as P2Y~1~ (43.0%), P2Y~2~ (47.7%), P2Y~4~ (48.2%), and P2Y~11~ (31.6%).

UDP **4** is a selective agonist at the P2Y~6~ receptor. UDP-β-S **10** (EC~50~ = 47 nM) is more potent than UDP (EC~50~ = 300 nM) in activation of the P2Y~6~ receptor and is more stable toward ectonucleotidases. 5-Br-UDP (EC~50~ = 800 nM) and the dinucleotide triphosphate (**71**, INS48823) are potent and/or stable agonists of the P2Y~6~ receptor (EC~50~ = 125 nM) \[[@CR72], [@CR78]\] (Figs. [1](#Fig1){ref-type="fig"} and [5](#Fig5){ref-type="fig"}). The SAR and molecular modeling of the uracil nucleotide-activated P2Y~6~ receptor were investigated recently \[[@CR79], [@CR80]\]. Novel UDP analogues were synthesized and assayed for activity at the human P2Y~6~ receptor.

The P2Y~6~ receptor is generally selective for 5′-diphosphate derivatives. Thus, uridine 5′-monophosphate, 2′-deoxyuridine 3′,5′-bisphosphate, a cyclic 3′,5′-diphosphate analogue, and a uridine 3′-diphosphate derivative are inactive as either agonists or antagonists.

Within a series of uracil dinucleoside 5′,5′-polyphosphates, the triphosphates (**68b** and **71)** are the most potent and selective (EC~50~ = 0.2 and 0.125 μM). The simple Up~2~U **68a** displays low potency at the P2Y~6~ receptor.

Modification of ribose hydroxyl groups of UDP has not yielded more potent P2Y~6~ receptor agonists. Substitution with a 2′-azido or 2′-amino group reduces potency at the P2Y~6~ receptor. Removal of either the 2′- or 3′-hydroxyl group of UDP yields a \>100-fold decrease in potency. The (S) conformation of the ribose moiety is preferred for ligand recognition by the P2Y~6~ receptor \[[@CR79]\]. A UDP derivative locked in the (N) conformation by an (N)-methanocarba ring is completely inactive, and the 2′-deoxy-(S)-methanocarba derivative **67** is moderately potent in activating the P2Y~6~ receptor (Fig. [5](#Fig5){ref-type="fig"}A). This is a rare example of the use of molecular modeling to predict the conformational preference in a putative GPCR binding site for rational ligand design. The computational prediction led to the subsequent synthesis of a novel analogue containing a rigid carbocyclic ribose substitute that is more potent than the corresponding 9-(2′-deoxyriboside) as a P2Y~6~ agonist.

The uracil ring was modified at the 2-, 3-, 4-, and 5-positions. Modification at the 3-position with N-CH~3~ markedly decreases potency, but halogenation of the 5-position in the iodo analogue **66** (Fig. [5](#Fig5){ref-type="fig"}A) yields a molecule that is equal in potency (EC~50~ = 0.15 µM) to UDP and is similar in potency to a 5-bromo analogue previously reported to be roughly equipotent to UDP \[[@CR80]\]. A 5-iodo modification maintains potency at the P2Y~6~ receptor, and 5-halo substitution of the uracil ring may therefore provide a basis for achieving selectivity at this subtype. In a series of uracil-modified compounds, 2-thio-UDP (EC~50~ = 0.06 μM) and 4-thio-UDP (EC~50~ = 0.08 μM) are five- to six-fold less potent than UDP. 4-Thioether derivatives and 4-carboxyalkylthio derivatives exhibit lower potency than the parent compound 4-thio-UDP. 3-Phenacyl-UDP **65** (EC~50~ = 70 nM) is a potent and selective P2Y~6~ receptor agonist \[[@CR81]\].

Only one class of antagonists of the P2Y~6~ receptor has been reported. The diisothiocyanate derivative MRS2578 **55** (EC~50~ = 0.037 μM) is a potent, insurmountable antagonist of P2Y~6~ nucleotide receptors \[[@CR82]\] (Fig. [4](#Fig4){ref-type="fig"}). Related compounds **56** and **57** have varied selectivity for P2Y receptor subtypes. These isothiocyanate derivatives likely bind covalently to P2Y receptors; they are hydrophobic and have limited stability in aqueous solution.

SAR of P2Y~14~ receptor for UDP-sugars {#Sec10}
--------------------------------------

The most atypical P2Y receptor is the P2Y~14~ receptor, which is distributed in the immune system, including in dendritic cells and the central nervous system. The identity of amino acid residues of TM domains of the P2Y~14~ receptor with P2Y~12~ and P2Y~13~ subtypes is 57.0% and 52.8%, respectively. However, in contrast to other P2Y receptors, the P2Y~14~ receptor is not activated by uridine 5′-di- or triphosphates or by adenine nucleotides \[[@CR83]\]. The P2Y~14~ receptor is the only subtype to respond principally to UDP-glucose **5** (EC~50~ = 0.35 μM) and other UDP-sugars, such as UDP-glucuronic acid **75** (EC~50~ = 102 nM), and the endogenous nucleotides UDP-galactose **76** (EC~50~ = 0.67 μM) and UDP-*N*-acetylglucosamine **77** (EC~50~ = 4.38 μM) (Fig. [5](#Fig5){ref-type="fig"}C). The SAR of analogues of UDP-glucose at the P2Y~14~ receptor was recently systematically explored \[[@CR84]\]. Novel analogues modified on the nucleobase, ribose moiety, and glucose moieties were synthesized and characterized biologically at the recombinant human P2Y~14~ receptor.

The P2Y~14~ receptor appears to be the most restrictive of the P2Y family with respect to modification of the nucleobase, ribose, and phosphate moieties. Most of the novel analogues of **5** modified on the uracil or ribose moieties are inactive. All compounds modified at the 5-position of uracil moiety (i.e., with azido, amino, and iodo) or at the 2′, 3′ hydroxy groups of ribose ring are inactive. Analogues with other nucleosides, such as adenosine, guanosine, cytidine, thymidine, deoxyuridine and deoxycytidine, are inactive. The dinucleotides Up~2~U **68a** and Up~4~U **68c** are inactive at the P2Y~14~ receptor.

Among the analogues of **5**, a 2-thiouracil analogue, MRS2690 **78**, is tenfold more potent (EC~50~ = 49 nM). A 4-thiouracil (EC~50~ = 0.29 μM) analogue is equipotent to **5**, but a 4-methyl-4-thiouracil moiety is not tolerated. The 2- and 4-thio modifications preserve potency at all uracil nucleotide-responsive subtypes but most effectively at the P2Y~2~ and P2Y~4~ receptors.

The high potency of analogues **75 (**UDP-glucuronic acid**)** and **76 (**UDP-galactose**)** suggests a flexibility of structural modification at the glucose C4 and C6 positions. The 12-fold-lower potency of **77** (UDP-N-acetylglucosamine) in comparison with **5** suggests a limited tolerance for steric bulk at the glucose C2 position. Modification of the glucose moiety of **5** to yield, for example, UDP-fructose, UDP-mannose, and UDP-inositol, preserved agonist potency at the P2Y~14~ receptor, as predicted in a modeling study \[[@CR85]\].

Conclusion {#Sec11}
==========

The medicinal chemistry of several of the P2Y receptors has recently acquired detailed qualitative and quantitative SARs. Selective agonists (for P2Y~1~, P2Y~2~, and P2Y~6~ receptors) and selective antagonists (for P2Y~1~, P2Y~2~, P2Y~6~, P2Y~11~, P2Y~12~, and P2Y~13~ receptors) have been identified. At the P2Y~1~ and P2Y~12~ receptors, 5′-diphosphate agonist derivatives have been transformed into potent and selective antagonists by alteration of the phosphate moieties and nucleobase and substitution pattern and introduction of carbocyclic substitution of the ribose moiety. Empirical and computational methods have identified conformations of the ribose moiety that enhance affinity at the P2Y~1~ and P2Y~6~ receptors have been identified through---and these conformations have been chemically locked to provide novel---selective ligands.

Screening of chemically diverse compound libraries has begun to yield new lead compounds for the development of P2Y receptor antagonists, e.g., directly acting P2Y~12~ receptor antagonists with antithrombotic activity. Challenges remaining include identification of selective agonists for the P2Y~4~, P2Y~11~, and P2Y~13~ receptors and of selective antagonists for the P2Y~4~ and P2Y~14~ receptors. The discovery of new, selective P2Y receptor ligands and optimization of existing structural leads hold promise for the identification of new clinical agents that exploit nucleotide receptor signalling.
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